The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMXC.L Share News (MXC)

  • There is currently no data for MXC

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: MGC cuts costs; Ince gets Arden sale green light

Tue, 03rd Jan 2023 17:17

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

NetScientific PLC - life sciences and sustainability technology investment firm - Notes that its portfolio company PDS Biotechnology Corp entered an exclusive global license agreement with Merck KGaA for the tumour-targeting IL-12 fusion protein M9241. "We are pleased to have partnered with Merck KGaA, Darmstadt, Germany to advance the development of M9241, a highly innovative cytokine therapy," PDS Chief Executive Officer & President Frank Bedu-Addo says. Merck is to pick up an equity stake in PDS.

----------

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Implements further cost reductions, enabling the company to direct a more significant portion of its working capital to its clinical trial and research programmes in 2023. Agrees to an immediate 35% reduction in director fees, effective from December 1. Adds that it agreed to a 10% to 20% reduction in their cash remuneration. Believes that this approach is appropriate in the current economic climate.

----------

Ince Group PLC - Legal services company - Receives approval from the Financial Conduct Authority for the change of control of its subsidiary Arden Partners PLC upon the completion of the disposal. Adds that the completion remains subject to approval from Ince's principal lending bank and "no material adverse event occurring prior to completion." The agreement for Zeus Group Ltd to acquire the entire issued share capital of Arden was reached in November. Ince itself had only sealed the acquisition of Arden in April, in a deal worth GBP10 million.

----------

Eagle Eye Solutions Group PLC - London-based marketing solutions provider - Completes the acquisition of Untie Nots and its subsidiaries. The company agreed on the terms for the acquisition of Arden for an initial consideration of EUR15.0 million in November.

----------

Angus Energy PLC - London-based oil and gas development company - Produces and sells gas volumes equal to 5.6 million therms in total for October, November and December combined. This equals 1.9 million therms per month. Says that average daily flow rates were highest in November at 6.0 million standard cubic feet per day. Notes that cold weather related issues have now been overcome. Says that the present drilling operations on the final horizontal section of the SF-07 side track are scheduled to resume on January 5.

----------

Beacon Energy PLC - Isle of Man, UK-based oil and gas company - Says Tulip Oil Holding BV shareholders have approved Beacon's acquisition of Rhein Petroleum GmbH. Proposes to appoint Stewart MacDonald as chief financial officer, subject to the completion of the acquisition.

----------

San Leon Energy PLC - oil and gas production, development and exploration in Nigeria - Extends the deadline for new debt facilities with Midwestern by 3 months to March 31.

----------

Canadian Overseas Petroleum Ltd - Calgary-based international oil and gas firm - Signs an agreement for the issue of 2025 convertible bonds with the total value of USD4 million. The conversion price is USD0.1583 per share for each USD200,000 of 2025 principal outstanding. Anticipates signing a debt refinancing term sheet in January and closing the debt refinancing in the first quarter of 2023. 

----------

MetalNRG PLC - investor in natural resources and energy - Says Pierpaolo Rocco withdrew his unfair prejudice claim against the company on December 23. Explains that former director Rocco brought a claim against the company and its directors, in a personal capacity for unfair prejudice towards him. Looks forward to the final agreement and settlement of costs. Notes "various materials" published on social media by Edward Spencer in connection with the requisitioned general meeting. Does not intend to comment on the other information published on social media. Remains committed to responding to any concerns from shareholders through the usual channels.

----------

Gulf Marine Services PLC - United Arab Emirates-based lift boat company - Issues warrants over 137.1 million shares at GBP0.0575 to lenders. Adds that the warrants are exercisable until June 2025.

----------

By Abby Amoakuh, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
1 Sep 2022 17:52

TRADING UPDATES: Strong interim results from Johnson Service, Eurocell

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
25 Aug 2022 16:26

TRADING UPDATES: Malvern revenue jumps; Rockwood eyes Main Market

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
18 Aug 2022 11:57

IN BRIEF: Graft Polymer wins first commercial order for GraftBio

Graft Polymer (UK) PLC - London-based company focused on the development and production of polymer modification, biological supplements, and nano-drug delivery systems - Wins first commercial purchase order for its GraftBio division. Order for 50,000 units of its anti-inflammatory supplement, ArtemiC Rescue from MGC Pharmaceuticals PLC. Order worth around USD1 million. Production to start immediately. Delivery expected over the next three months. Chief Executive Victor Volduev says he expects follow-on orders in the coming quarters.

Read more
17 Aug 2022 11:12

MGC shares rise on USD1 million order for ArtemiC

(Alliance News) - MGC Pharmaceuticals Ltd shares were lifted on Wednesday after it announced a USD1 million order for its neutraceutical, ArtemiC.

Read more
15 Aug 2022 17:31

IN BRIEF: MGC Pharma's CannEpil found safe for driving in study

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Says clinical study results for its epilepsy treatment, CannEpil, are complete. The study found CannEpil to be safe for post-treatment driving activities. It used a driving simulator to test whether the drug caused somnolence, ie drowsiness, or impairs cognition. It was sponsored by Cannvalate Australia, and conducted by the Centre of Human Psychopharmacology at Swinburne University of Technology, under the Medical Cannabis Research Collaboration.

Read more
5 Aug 2022 14:58

TRADING UPDATES: 4D Pharma warns of wind-up; Star Phoenix files claim

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and Wednesday and not separately reported by Alliance News:

Read more
29 Jul 2022 19:36

TRADING UPDATES: Walker Crips assets grow; Minoan interim loss narrows

(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Friday and not separately reported by Alliance News:

Read more
28 Jul 2022 20:08

TRADING UPDATES: Scottish American outperforms; Amte picks Dundee

(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
25 Jul 2022 21:53

IN BRIEF: MGC Pharmaceuticals quarterly sales "strong"

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Says "strong" quarterly sales continue, notes AUD1.6 million, about GBP923,000, in cash receipts during three month period to June 30. In 12-month period, records AUD6.1 million in cash receipts.

Read more
14 Jul 2022 21:44

TRADING UPDATES: Shield closer to Canada approval; Angle plans raise

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
8 Jul 2022 14:19

IN BRIEF: MGC Pharmaceuticals wins approval for Covid study, shares up

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Receives approval from South African Health Products Regulatory Authority for a Phase 2b dose finding study of its nanoparticle formulation CimetrA on patients diagnosed with Covid-19.

Read more
6 Jul 2022 20:08

IN BRIEF: MGC Pharmaceuticals launches medical data app ZAM

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Says it is set to launch a real-time data collection application, ZAM, for use across the pharmaceutical and health care sectors, in collaboration with software development company, Caba Tech. The app will be available during the third quarter and will enable patients to log their medical history and monitor their medication use. ZAM, through the collection the patient data, will also provide users with a more complete understanding of their health and treatments, it says.

Read more
27 Jun 2022 20:27

IN BRIEF: MGC's CimetrA shows promise beyond Covid applications

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Says preliminary results from pre-clinical in vitro study of CimetrA show it could have "wide-ranging application" as anti-inflammatory treatment. This is through the treatment's modulation of the production of pro-inflammatory cytokines. The study was undertaken by Israeli contract research organisation, Science in Action. Results support previous findings from a 2020 study into Covid-19, which showed CimetrA modulates the body's production of cytokines, which can lead to a cytokine storm, a type of severe immune reaction. New results support the potential of CimetrA to have a wider-ranging application as anti-inflammatory treatment, beyond the treatment of Covid-19 symptoms.

Read more
24 Jun 2022 10:13

IN BRIEF: MGC Pharma moves ahead with Covid-19 treatment in US

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Progresses plans to begin US clinical trial for its Covid-19 treatment CimetrA, as MGC and AMC Holdings Inc executives meet with department heads from the University of South Florida. Parties also discuss regulatory approvals for phytocannabinoid medicines CogniCann and CannEpil in the US for early patient access schemes. Says US market access and distribution agreement has been signed with minimum orders of USD24 million over three years, including CimetrA.

Read more
16 Jun 2022 13:43

IN BRIEF: MGC Pharmaceuticals completes research study on brain cancer

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Completes an in-vitro preclinical research study with the National Institute of Biology into the use of cannabinoids to treat brain cancer. The company says the study, undertaken on 30 biopsy samples from 18 patients over a period of three years, sought to determine the optimal formulation for the treatment of Glioblastoma, a form of brain cancer. The study showed that MGC Pharma's proprietary formulations were cytotoxic to Glioblastoma tumour and stem cells, reducing the cells' viability and inducing caspase-dependent cell apoptosis, or cell death.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.